|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CPD |
Gene summary for CPD |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CPD | Gene ID | 1362 |
| Gene name | carboxypeptidase D | |
| Gene Alias | GP180 | |
| Cytomap | 17q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | O75976 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1362 | CPD | LZE2T | Human | Esophagus | ESCC | 5.59e-08 | 5.23e-01 | 0.082 |
| 1362 | CPD | LZE4T | Human | Esophagus | ESCC | 1.60e-10 | 2.34e-01 | 0.0811 |
| 1362 | CPD | LZE5T | Human | Esophagus | ESCC | 1.99e-06 | 2.05e+00 | 0.0514 |
| 1362 | CPD | LZE7T | Human | Esophagus | ESCC | 1.97e-04 | 2.11e-01 | 0.0667 |
| 1362 | CPD | LZE20T | Human | Esophagus | ESCC | 2.50e-02 | 1.44e-02 | 0.0662 |
| 1362 | CPD | LZE22T | Human | Esophagus | ESCC | 1.43e-03 | 1.36e-01 | 0.068 |
| 1362 | CPD | LZE24T | Human | Esophagus | ESCC | 1.85e-17 | 5.22e-01 | 0.0596 |
| 1362 | CPD | LZE21T | Human | Esophagus | ESCC | 1.43e-05 | 3.37e-01 | 0.0655 |
| 1362 | CPD | LZE6T | Human | Esophagus | ESCC | 2.67e-04 | 4.78e-02 | 0.0845 |
| 1362 | CPD | P2T-E | Human | Esophagus | ESCC | 1.33e-20 | 4.56e-01 | 0.1177 |
| 1362 | CPD | P4T-E | Human | Esophagus | ESCC | 5.68e-09 | 2.76e-01 | 0.1323 |
| 1362 | CPD | P5T-E | Human | Esophagus | ESCC | 6.48e-04 | 9.52e-02 | 0.1327 |
| 1362 | CPD | P8T-E | Human | Esophagus | ESCC | 3.57e-36 | 9.35e-01 | 0.0889 |
| 1362 | CPD | P9T-E | Human | Esophagus | ESCC | 2.19e-05 | 1.78e-01 | 0.1131 |
| 1362 | CPD | P10T-E | Human | Esophagus | ESCC | 5.11e-12 | 1.73e-02 | 0.116 |
| 1362 | CPD | P11T-E | Human | Esophagus | ESCC | 1.29e-02 | 4.13e-01 | 0.1426 |
| 1362 | CPD | P12T-E | Human | Esophagus | ESCC | 5.80e-24 | 3.26e-01 | 0.1122 |
| 1362 | CPD | P15T-E | Human | Esophagus | ESCC | 1.36e-19 | 5.10e-01 | 0.1149 |
| 1362 | CPD | P16T-E | Human | Esophagus | ESCC | 1.16e-14 | 3.05e-01 | 0.1153 |
| 1362 | CPD | P17T-E | Human | Esophagus | ESCC | 4.09e-07 | 2.15e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00605375 | Cervix | CC | muscle tissue development | 76/2311 | 403/18723 | 9.76e-05 | 1.27e-03 | 76 |
| GO:00147064 | Cervix | CC | striated muscle tissue development | 72/2311 | 384/18723 | 1.76e-04 | 2.07e-03 | 72 |
| GO:00075173 | Cervix | CC | muscle organ development | 58/2311 | 327/18723 | 2.73e-03 | 1.85e-02 | 58 |
| GO:00075192 | Cervix | CC | skeletal muscle tissue development | 30/2311 | 155/18723 | 7.97e-03 | 4.18e-02 | 30 |
| GO:00160422 | Colorectum | MSS | lipid catabolic process | 77/3467 | 320/18723 | 7.43e-03 | 4.71e-02 | 77 |
| GO:00442422 | Colorectum | FAP | cellular lipid catabolic process | 49/2622 | 214/18723 | 2.87e-04 | 3.77e-03 | 49 |
| GO:00160423 | Colorectum | FAP | lipid catabolic process | 65/2622 | 320/18723 | 1.13e-03 | 1.08e-02 | 65 |
| GO:00066502 | Colorectum | FAP | glycerophospholipid metabolic process | 62/2622 | 306/18723 | 1.54e-03 | 1.38e-02 | 62 |
| GO:00066442 | Colorectum | FAP | phospholipid metabolic process | 74/2622 | 383/18723 | 2.24e-03 | 1.83e-02 | 74 |
| GO:00066503 | Colorectum | CRC | glycerophospholipid metabolic process | 55/2078 | 306/18723 | 2.10e-04 | 3.55e-03 | 55 |
| GO:00066443 | Colorectum | CRC | phospholipid metabolic process | 65/2078 | 383/18723 | 3.21e-04 | 4.95e-03 | 65 |
| GO:00464861 | Colorectum | CRC | glycerolipid metabolic process | 64/2078 | 392/18723 | 1.01e-03 | 1.19e-02 | 64 |
| GO:00160424 | Colorectum | CRC | lipid catabolic process | 53/2078 | 320/18723 | 1.89e-03 | 1.93e-02 | 53 |
| GO:0060537 | Colorectum | CRC | muscle tissue development | 63/2078 | 403/18723 | 3.17e-03 | 2.78e-02 | 63 |
| GO:00442423 | Colorectum | CRC | cellular lipid catabolic process | 37/2078 | 214/18723 | 4.16e-03 | 3.40e-02 | 37 |
| GO:0014706 | Colorectum | CRC | striated muscle tissue development | 59/2078 | 384/18723 | 6.11e-03 | 4.47e-02 | 59 |
| GO:00605376 | Endometrium | AEH | muscle tissue development | 83/2100 | 403/18723 | 2.57e-08 | 1.50e-06 | 83 |
| GO:00147065 | Endometrium | AEH | striated muscle tissue development | 75/2100 | 384/18723 | 1.06e-06 | 3.62e-05 | 75 |
| GO:00075174 | Endometrium | AEH | muscle organ development | 60/2100 | 327/18723 | 8.19e-05 | 1.22e-03 | 60 |
| GO:00605382 | Endometrium | AEH | skeletal muscle organ development | 30/2100 | 166/18723 | 5.64e-03 | 3.46e-02 | 30 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CPD | SNV | Missense_Mutation | rs375764127 | c.1927N>G | p.Gln643Glu | p.Q643E | O75976 | protein_coding | tolerated(1) | benign(0.007) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| CPD | SNV | Missense_Mutation | c.3388N>A | p.His1130Asn | p.H1130N | O75976 | protein_coding | tolerated(0.14) | probably_damaging(0.998) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| CPD | SNV | Missense_Mutation | novel | c.4027N>A | p.Glu1343Lys | p.E1343K | O75976 | protein_coding | deleterious_low_confidence(0.02) | benign(0.073) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CPD | SNV | Missense_Mutation | c.2153N>C | p.Arg718Thr | p.R718T | O75976 | protein_coding | tolerated(0.74) | benign(0.01) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| CPD | SNV | Missense_Mutation | novel | c.2509N>T | p.Pro837Ser | p.P837S | O75976 | protein_coding | deleterious(0) | possibly_damaging(0.904) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| CPD | SNV | Missense_Mutation | novel | c.3812N>T | p.Ser1271Leu | p.S1271L | O75976 | protein_coding | tolerated(0.22) | benign(0.076) | TCGA-OL-A66L-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CPD | insertion | In_Frame_Ins | novel | c.2107_2108insATCAAAAACTTT | p.Ile703delinsAsnGlnLysLeuLeu | p.I703delinsNQKLL | O75976 | protein_coding | TCGA-AQ-A04H-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | ||
| CPD | insertion | Frame_Shift_Ins | novel | c.2109_2110insT | p.Ala704CysfsTer15 | p.A704Cfs*15 | O75976 | protein_coding | TCGA-AQ-A04H-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | ||
| CPD | SNV | Missense_Mutation | rs377211802 | c.1088N>A | p.Arg363Gln | p.R363Q | O75976 | protein_coding | tolerated(0.68) | benign(0.007) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CPD | SNV | Missense_Mutation | novel | c.2840N>C | p.Val947Ala | p.V947A | O75976 | protein_coding | tolerated(0.52) | benign(0.171) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1362 | CPD | ENZYME, DRUGGABLE GENOME, PROTEASE | ANTISERUM | 9490632 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |